佰泽医疗(02609)发布中期业绩 股东应占亏损2762万元 同比扩大139.18%

Core Viewpoint - Baize Medical (02609) reported a mid-term performance for the six months ending June 30, 2025, showing a slight increase in revenue but a significant increase in shareholder losses [1] Financial Performance - Revenue reached 575 million RMB, representing a year-on-year increase of 0.66% [1] - Shareholder losses amounted to 27.62 million RMB, which is a year-on-year increase of 139.18% [1] - Basic loss per share was reported at 0.02 RMB [1]